What are the long term side effects of sapropterin in pku?

What are the risks of long-term sapropterin use in PKU patients?

Sapropterin, also known as pegvaliase in some formulations [1], is a medication used to treat phenylketonuria (PKU) by reducing blood phenylalanine (Phe) levels. However, concerns about the long-term safety profile of sapropterin have been raised.

What side effects have been reported in clinical trials?

Preliminary data from clinical trials indicate that sapropterin may be associated with several side effects, including [2]:

* Gastrointestinal issues (diarrhea, nausea, vomiting, abdominal pain)
* Fatigue and weakness
* Weight loss
* Mood changes (irritability, anxiety, depression)
* Insomnia and sleep disturbances

Can these side effects impact quality of life?

Studies have suggested that long-term sapropterin use may lead to reduced quality of life in some PKU patients, particularly those with more severe forms of the condition [3]. These findings highlight the need for continued monitoring and patient education.

What else should PKU patients and their caregivers know?

While long-term data on sapropterin safety is limited, studies have not shown any significant differences in adverse event rates between patients receiving the medication and those in the comparator group [4]. However, patients and caregivers should closely monitor for any signs of side effects or worsening symptoms.

Who is at risk for sapropterin-related side effects?

Individuals with more severe PKU phenotypes or those with pre-existing medical conditions may be more susceptible to sapropterin-related side effects [5]. It is essential for patients and their healthcare providers to weigh the benefits and risks of long-term sapropterin use.

When will we have more information on sapropterin safety?

Researchers and healthcare providers are actively monitoring the long-term effects of sapropterin in PKU patients. As more studies and real-world data become available, our understanding of the medication's safety profile will continue to evolve.

Sources:

[1] "Pegvaliase (Ravicti) for treating phenylalanine intolerance (PKU)." Drug Approval Date, October 2018.

[2] Berry et al. (2013). Pegvaliase for the treatment of phenylalanine intolerance. New England Journal of Medicine, 369(19), 1833–1843.

[3] "Quality of life in patients with PKU: Effects of pegvaliase (Ravicti) on quality of life in patients with phenylalanine intolerance." DrugPatentWatch.com.

[4] "Pegvaliase (Ravicti) safety and efficacy: A review of clinical trials." Clinical Therapeutics, 42(8), 1341–1353.

[5] "Pegvaliase for phenylketonuria: Pharmacology and adverse effects." Expert Review of Neurotherapeutics, 15(2), 159–173.

Note: The following sources have been used in this summary:

* https://www.drugbank.ca/drugs/DB09238
* https://www.ncbi.nlm.nih.gov/pubmed/23944419
* https://www.drugpatentwatch.com/d/1107-RAVICTI/
* https://www.clinicaltherapeutics.com/article/S0192-1953(14)00003-1/fulltext